News from the world of biotech
This is an older exclusive article for FinFeed subscribers which is now opened up. If you'd like to see new exclusive articles every week, please subscribe to our newsletter.
Growing up, I never had any real interest in science or technology.
(A bit rich coming from the person bringing you this biotech-themed newsletter I admit, but it’s true.)
I was never any good at maths. And physics — forget about it.
I did have a passing interest in biology, but that was short-lived after a chemical mix up sent a spark from the test tube down the front of my school shirt, incinerating the birthmark on my chest. I don’t know if that says more about my inability as a scientist, or the lack of safety in schools in the 1980s.
Probably a bit of both. But I digress...
What I have developed as time has gone by is an interest in research and development for various cancers. Cancer has taken the lives of several family friends and I have a young niece currently in remission.
Heart disease and diabetes also run in the family. So I keep a keen eye on any progress made by biotech and medtech companies with regards to potential cures and preventions for a whole range of conditions.
Medical diagnostics innovator Rhythm Biosciences is in the process of preparing reagents for its ColoSTATTM blood test, which tests for colorectal cancer. Prescient Therapeutics is working in the field of breast cancer, bringing two novel cancer drugs to the table.
As we move forward to cover a broader church in this space on Finfeed, some of the companies will be ASX listed entities; others will be unlisted companies (which may not be suitable for retail investors) working for the greater good to eradicate various diseases.
We’ll also take a look at what’s happening in the various sectors that make up the biotech landscape including agricultural biotechnology, plant biotechnology, nutrient, industrial and more... and we’ll link you to articles such as How Plant Biotechnology Can Give Us Better Food and Medicines.
The importance of being Biotech
Put simply, biotech is technology based on biology. The highschool kid in me shudders at the thought. The adult in me says No, no — keep going. I want to hear more about it.
Here's another definition from USC News: “Biotech uses the cellular and molecular processes that occur in living organisms to create products that treat diseases, improve agriculture and reduce our environmental footprint.
“Modern biotechnology provides breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes.” (Read the full USC article here.)
The importance of biotech shouldn’t be underestimated, considering it can lead to tailor-made cures, eradication of diseases, better diagnostics and an overall healthier society.
(Maybe it could even regenerate my birthmark. A man can hope!)
I'm looking forward to bringing you a weekly rundown of my findings and thoughts on this exciting sector — so stay tuned.
This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.